What You Should Know:
- Elmiron®, a prescription drug used to treat bladder pain or discomfort from interstitial cystitis, has been linked to a serious vision disorder called pigmentary maculopathy.
- This condition resulting from Elmiron® use can be confused with or initially diagnosed as age-related macular degeneration, macular or pattern dystrophy, diabetic retinopathy, or certain other genetic retinal diseases.
- Lawsuits have been filed by individuals who have developed vision problems after taking Elmiron®.
- The lawsuits accuse the prescription drug manufacturers of manufacturing, marketing, and selling a pharmaceutical which they knew or should have known could cause eye issues, yet did not properly warn consumers, physicians, or the public.
- Contact Borgess Law, LLC at (567) 455-5955 or toll-free at (844) LAW-9144 for a free, confidential and no-obligation consultation for additional information or if you believe you or a loved one could have a potential claim.
Elmiron® is an FDA approved oral medication prescribed for interstitial cystitis. Interstitial cystitis is a chronic regional pain syndrome of the bladder and pelvis that predominately affects females, manifesting with urinary urgency and pain or discomfort. More than 1 million people in the United States are estimated to be affected by this condition, which can also disrupt sleep and lead to emotional stress. Elmiron® is thought to act by binding to the bladder’s epithelial lining, regulating irritation and cellular permeability
Link to Eye Damage
Multiple scientific studies have linked Elmiron® to a specific type of progressive and permanent eye disease called pigmentary maculopathy. Sometimes this condition resulting from Elmiron® use can be confused with or initially diagnosed as age-related macular degeneration, macular or pattern dystrophy, diabetic retinopathy, or certain other genetic retinal diseases.
What Are the Symptoms of Pigmentary Maculopathy?
Reported symptoms for patients experiencing potential Elmiron®-associated eye damage include:
- Prolonged light to dark adaptation
- Blurry vision
- Difficulty reading
- Metamorphopsia (lines look curvy)
- Central vision loss
- Loss of vision detail
- Dimming of vision
- Blind splits
- Impaired color vision
- Difficulty with near vision
Lawsuits have been filed against various pharmaceutical manufactures by individuals who have suffered vision loss or other eye problems from taking Elmiron®. The lawsuits allege that the drugmakers failed to properly warn consumers, physicians, and the public that Elmiron® could cause vision significant visual damage, including pigmentary maculopathy.
How We Can Help:
Borgess Law, LLC is currently reviewing potential legal claims for individuals who have experienced eye or vision problems after taking Elmiron®. There is no charge for this review. Further, if the claim is one we are willing to pursue, there is no fee or expense owed unless a recovery is obtained.
Attorney Pamela Borgess, the founder of Borgess Law, LLC, has decades of experience with numerous national high-profile defective medical drug/device cases and can discuss your legal options. For more information about the Elmiron® litigation or to discuss a potential claim, contact Borgess Law at (567) 455-5955 or toll-free at (844) LAW-9144. You can also contact Borgess Law by submitting an online inquiry. Again, this consultation is free and confidential. We welcome any questions you may have.
*This blog does not contain medical advice and is not intended to substitute for professional medical advice, diagnosis, or treatment. Please consult with your physician for personalized medical advice.